Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Moderna and ROVI Expand mRNA Manufacturing Collaboration | Contract Pharma
Breaking News, Collaborations & Alliances

Moderna and ROVI Expand mRNA Manufacturing Collaboration

Includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain.

Moderna and Laboratorios Farmacéuticos Rovi, S.A., a pan-European pharmaceutical company specializing in the research, development, contract manufacturing and marketing of small molecules and biologics, have entered a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling and packaging of ROVI’s facilities, located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.

This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI’s facilities in Madrid, Spain. In addition to producing Moderna’s COVID-19 vaccine, ROVI’s platform could also be utilized to service future Moderna mRNA vaccine candidates.

“ROVI has been a pivotal partner in supporting the manufacturing of our COVID-19 mRNA vaccine for countries outside of the U.S., and this long-term agreement expands our partnership and allows for further scale-up for future mRNA medicines,” said Juan Andres, chief technical operations and quality officer, Moderna.

Juan López-Belmonte Encina, chairman and CEO, Rovi, said, “We are delighted to expand our collaboration with Moderna and become a long-term manufacturing partner. At ROVI, we are working to contribute all our experience as a high-technological-value contract manufacturer of injectables to the solution of this pandemic, and we are confident of our ability to take part in the manufacturing of new mRNA candidates in the future.”

Moderna and Rovi are expected to finalize details of this agreement in the first quarter of 2022.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters